Immix Biopharma Inc IMMX announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd BGNE / Novartis AG's NVS tislelizumab, for advanced solid tumors.
100% Tumor Shrinkage at two months was observed in advanced metastatic colorectal cancer demonstrated by IMX-110 + tislelizumab combination in the first cohort of patients who received the lowest IMX-110 dose.
Tumor shrinkage was observed in the first two out of two (2/2) evaluable patients (100%) at two months.
The company compares the data with Merck & Co Inc's MRK anti-PD-1 antibody Keytruda (pembrolizumab) alone produced tumor shrinkage in 3 of 19 patients (16%) with an evaluable postbaseline tumor assessment in Phase 1b study of pembrolizumab in patients with advanced or metastatic colorectal cancer according to O'Neil et al., 2017.
No dose-limiting toxicities have been observed in the first cohort. Hence the trial can now enroll the next cohort of three patients at a higher dose of IMX-110 + tislelizumab.
Immix Biopharma is enrolling the next higher dose cohort of IMX-110 + anti-PD-1 antibody tislelizumab in advanced solid tumors.
Price Action: IMMX shares are down 5.17 at $2.75 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
